Please assess the completion status of the following clinical trial:

Trial Title: NORSPAN Transdermal Patches Phase III Study In Non-Cancer Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females age are ≥20 ,≤80 years.~* Clinical diagnosis of musculoskeletal pain for 4 weeks or longer with non-malignant pain etiology at Visit 1.~* Subject is a current user of NSAIDS or paracetamol and reports a history of insufficient therapeutic benefit in musculoskeletal pain.~* Subjects must record an 'average pain over the last week at study institution' score at primary pain site of ≥ 4 on an 11-point numerical pain rating scale.~* Subjects must be able to understands the study procedures and assessment, and agree to participate in the study by giving written informed consent.~Exclusion Criteria:~* Subjects who have been taking long-acting or short-acting opioid analgesic formulations within the last 4 weeks.~* Subjects who have a current chronic disease(s) or who have a past history and high possibilities to relapse, in addition to their musculoskeletal pain, requiring frequent analgesic therapy.~* Subjects with clinically unstable respiratory disease, dysfunction of the biliary tract, thyroid disease, adrenal cortical insufficiency, prostatic hypertrophy requiring intervention or renal artery stenosis.~* Subject who have a past history of malignant neoplasm including leukemia and lymphoma.~* Subjects with clinically unstable, active or symptomatic heart disease.~* Subjects who have psychiatric disorder, uncontrolled seizures or convulsive disorder and so on.~* Subjects who have a current or past (within 5 years) history of substance or alcohol abuse, or subjects who give a positive result in drug abuse test during the Screening Period.~* Subjects scheduled for therapies within the study period which might effect study assessment.~* Females who are pregnant, lactating or have a possibility of being pregnant.~* Subjects with values \> 2 times the upper limit of normal for AST or ALT or total bilirubin at visit 1 or who have severe impaired liver function.~* Subjects with serum creatinine \> 2 mg/dL at Visit 1 or who have severe impaired renal function.~* Subjects with serum potassium \< 3.5 mEq/L at Visit 1.~* Subjects receiving hypnotics or other central nervous system (CNS) depressants.~* Subjects receiving monoamine oxidase inhibitor (MAOI) within 2 weeks before screening.~* Subjects who have a history of supersensitivity to study drug.~* Known intolerance to and/or lack of effect of tramadol.~* Subjects who participated in a clinical research study within 1 month of study entry.~* Subjects who participated previously in a BTDS study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Buprenorphine Transdermal System (Type: ACTIVE_COMPARATOR): None
- Tramadol CR (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).